Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 92 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2016', provides in depth analysis on Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted pipeline therapeutics. 

The report provides comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) 
- The report reviews Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Overview 8
Therapeutics Development 9
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Products under Development by Stage of Development 9
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Products under Development by Therapy Area 10
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Products under Development by Indication 11
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Products under Development by Companies 15
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Products under Development by Universities/Institutes 20
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Therapeutics Assessment 22
Assessment by Monotherapy/Combination Products 22
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 28
4SC AG 28
Acetylon Pharmaceuticals, Inc. 29
Chipscreen Biosciences Ltd 30
Curis, Inc. 31
GlaxoSmithKline Plc 32
HitGen LTD 33
Italfarmaco S.p.A. 34
MEI Pharma, Inc. 35
Merck & Co., Inc. 36
Rodin Therapeutics 37
Sigma-Tau S.p.A. 38
TetraLogic Pharmaceuticals 39
Yungjin Pharm. Co., Ltd. 40
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Drug Profiles 41
4SC-202 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ACY-738 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ACY-957 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
CS-3158 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
CUDC-907 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
givinostat - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
HG-3001 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Largazole - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
N-140 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
pracinostat - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
remetinostat - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecule to Inhibit HDAC2 for Oncology - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecules to Inhibit HDAC2 for Neurological Disorders - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
ST-3595 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
tucidinostat - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
vorinostat - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
YPL-001 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Dormant Projects 78
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Featured News & Press Releases 81
Aug 01, 2016: MEI Pharmas Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy 81
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 81
Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 82
May 04, 2016: Acetylon Pharmaceuticals Publishes New Mechanism for the Treatment of Sickle Cell Disease/Beta-Thalassemia with Selective HDAC1/2 Inhibition in PLoS One 82
Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 83
Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 83
Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 84
Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team 84
Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 85
Dec 07, 2015: MEI Pharma Announces Positive Results from Phase II Study of Pracinostat in Acute Myeloid Leukemia, Plans to Initiate Phase III Registration Study 85
Dec 07, 2015: Acetylon Presents Data on the Pharmacokinetics and HbE/HbG Hemoglobin Induction Following Once Daily Dosing of an Oral HDAC1,2 Inhibitor in Animal Models 86
Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting 87
Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting 89
Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 89
Oct 06, 2015: MEI Pharma Announces Data from Phase II Clinical Studies of Pracinostat Accepted for Oral Presentation at American Society of Hematology Annual Meeting 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Products under Development by Companies, H2 2016 (Contd..2) 18
Products under Development by Companies, H2 2016 (Contd..3) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Products under Investigation by Universities/Institutes, H2 2016 21
Assessment by Monotherapy/Combination Products, H2 2016 22
Number of Products by Stage and Mechanism of Action, H2 2016 24
Number of Products by Stage and Route of Administration, H2 2016 26
Number of Products by Stage and Molecule Type, H2 2016 27
Pipeline by 4SC AG, H2 2016 28
Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 29
Pipeline by Chipscreen Biosciences Ltd, H2 2016 30
Pipeline by Curis, Inc., H2 2016 31
Pipeline by GlaxoSmithKline Plc, H2 2016 32
Pipeline by HitGen LTD, H2 2016 33
Pipeline by Italfarmaco S.p.A., H2 2016 34
Pipeline by MEI Pharma, Inc., H2 2016 35
Pipeline by Merck & Co., Inc., H2 2016 36
Pipeline by Rodin Therapeutics, H2 2016 37
Pipeline by Sigma-Tau S.p.A., H2 2016 38
Pipeline by TetraLogic Pharmaceuticals, H2 2016 39
Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 40
Dormant Projects, H2 2016 78
Dormant Projects (Contd..1), H2 2016 79
Dormant Projects (Contd..2), H2 2016 80